EDIT — Editas Medicine, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1650664 ·
Last close
$1.83
Market Cap
$281.67M
52W High
$3.94
52W Low
$1.66
ADV30
2,381,819
Next earnings
2026-11-09
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 10,365,000 — -24,282,000 -23,393,000 219,412,000 93,169,000 134,892,000
Jun 2026 11,890,000 — -19,893,000 -18,230,000 237,364,000 181,815,000 132,083,000
Mar 2026 2,831,000 — -25,003,000 -24,982,000 149,338,000 123,648,000 144,930,000
Dec 2025 24,741,000 — -14,016,000 -5,620,000 186,534,000 146,645,000 159,246,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-110,206,000
Investing CF
$-96,666,000
Financing CF
$134,393,000
CapEx
$-691,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,695,108,000
Inventory
—
Receivables
$7,727,000
ST Investments
$97,029,000
EBIT TTM
$-69,474,000
Pretax Income TTM
$-72,225,000
Interest Exp TTM
$2,751,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$49,827,000
EBITDA
$-81,105,000
Free Cash Flow
$-34,032,624
Enterprise Value
$158,660,256
Total Cash
$190,198,000
Total Debt
$13,941,000
Shares Out
154,339,748
Trailing EPS
$-0.54
Book Value
$0.55
ROE
-147.4%
ROA
-24.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 40,520,000 -99,336,000 -160,060,000 186,534,000 159,246,000 27,288,000 -165,241,000
Dec 2024 32,314,000 -238,920,000 -237,093,000 341,589,000 207,315,000 134,274,000 -210,284,000
Dec 2023 78,123,000 -169,181,000 -153,219,000 499,153,000 150,056,000 349,097,000 -132,178,000
Dec 2022 19,712,000 -225,950,000 -220,432,000 514,321,000 153,641,000 360,680,000 -177,349,000

TTM Snapshot

Revenues TTM
$47,005,000
NetIncome TTM
$-73,949,000
OpCashFlow TTM
—
Assets (Latest)
$237,364,000
Forward EPS
$-0.72

Max Pain — expiry 2027-01-15

max pain strike: $2.00 · spot: $1.77 · call oi: 5,828 · put oi: 2,610
Expected Move to 2027-01-15: ±$0.80 (45.20%) — implied range $0.97 – $2.57 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AGEN AGENUS INC $280.98M $6.21 —
EIKN Eikon Therapeutics, Inc. $279.06M $5.15 —
TRXB TRex Bio, Inc. $274.46M $10.00 —
AUTL Autolus Therapeutics plc $290.12M $1.09 —
AGMB AgomAb Therapeutics NV $291.55M $5.92 —

News headlines (Yahoo Finance, 1h cache)

Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
2026-11-10 22:14 · Yahoo
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 12:25 · Yahoo
Editas: Q3 Earnings Snapshot
2026-11-09 12:14 · Yahoo
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
2026-10-29 15:30 · Yahoo
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
2026-10-14 13:00 · Yahoo
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
2026-10-09 14:53 · Yahoo
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
2026-10-08 17:25 · Yahoo
Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
2026-11-12 13:40 · Yahoo
What Will Decide Vertex Stock Over The Next Six Months?
2026-11-11 15:38 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.